<DOC>
	<DOCNO>NCT00002850</DOCNO>
	<brief_summary>RATIONALE : Giving antibiotic may effective prevent control early infection patient multiple myeloma may improve response chemotherapy . PURPOSE : This randomized clinical trial study antibiotic see well work compare antibiotic prevent early infection patient multiple myeloma .</brief_summary>
	<brief_title>Antibiotic Therapy Preventing Early Infection Patients With Multiple Myeloma Who Are Receiving Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate whether oral antibiotic prophylaxis co-trimoxazole ( TMP-SMX ) versus ciprofloxacin ( CPFX ) ofloxacin versus prophylaxis significantly reduce rate serious bacterial infection first 3 month chemotherapy patient multiple myeloma . - Determine whether antibiotic prophylaxis TMP-SMX CPFX ( ofloxacin ) associate increased incidence nonbacterial infection increase rate infection organism resistant prophylactic antibiotic . - Evaluate whether oral antibiotic prophylaxis CPFX ofloxacin effective TMP-SMX without associate toxic effect . - Evaluate whether protection early infection multiple myeloma patient improve response initial chemotherapy . OUTLINE : This randomize , multicenter study . Patients stratify participate center . Patients randomize 1 2treatment arm . - Arm I : Patients receive co-trimoxazole every 12 hour 2 month follow observation 2 month . - Arm II : Patients receive oral ciprofloxacin ofloxacin every 12 hour 2 month follow observation 1 month . - Arm III : The patient receive prophylaxis . Patients continue randomly assign treatment throughout infection addition treatment need infection . Patients also remain randomly assign treatment chemotherapy discontinue , change , delay 3 month study . Patients follow 6 month , 1 year , 2 year . PROJECTED ACCRUAL : A total 212 patient ( 71 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Inclusion : Patient must diagnosis multiple myeloma confirm presence : Bone marrow plasmacytosis &gt; 10 % abnormal plasma cell multiple biopsyproven plasmacytoma , least one criterion must document : 1 . Myeloma protein serum 2 . Myeloma protein urine ( free monoclonal light chain ) 3 . Radiologic evidence osteolytic lesion ( generalize osteoporosis qualifies bone marrow aspirate contains &gt; 20 % plasma cell ) Patients must active infection prior seven day antibiotic prior seven day . Patients receive radiotherapy precede ten day . Primary therapy multiple myeloma must start within three day entry study . For purpose eligibility study , myelosuppressive chemotherapy highdose dexamethasone base regimen acceptable primary therapy . The highdose dexamethasone regimen must include , minimum , dexamethasone 40 mg per day day 14 , 912 , 1720 first cycle 40 mg per day day 14 second cycle . Patients receive dexamethasone alone dexamethasone thalidomide among eligible protocol . Patients must serum creatinine &lt; 5.0 mg/dl require dialysis time study entry . If patient require dialysis enrollment , continue protocol use adjust medication guideline Written informed consent must obtain prior entry . Exclusion : Patients smolder myeloma , history hypersensitivity fluoroquinolones trimethoprim , bone marrow transplant autologous stem cell rescue plan first two month treatment , patient take theophylline , patient previously treat chemotherapy highdose dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>infection</keyword>
</DOC>